MedTrace Logo

RE-irradiation of Diffuse MIdline Glioma paTients

NCT06093165 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-10-23

No results posted yet for this study

Summary

The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.

Conditions

  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Diffuse Intrinsic Pontine Glioma
  • Diffuse Glioma
  • Pontine Tumors
  • Thalamic Tumor
  • Brain Tumor, Pediatric

Interventions

RADIATION

Re-irradiation

20Gy on 10 fractions

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Sahlgrenska University Hospital

    collaborator OTHER

  • Karolinska University Hospital

    collaborator OTHER

  • Radiumhospitalet, Oslo University Hospital

    collaborator UNKNOWN

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Maja V Maraldo · Department of oncology and radiotherapy, Copenhagen University Hospital Rigshospitalet

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2029-11-30
Completion
2029-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06093165 on ClinicalTrials.gov